95 related articles for article (PubMed ID: 21446005)
41. [Clinical features of benign prostatic hyperplasia complicated by chronic prostatitis].
Chang DG; Li GS; Zhang PH; Wu TL; Mei XF; Cao J; Gao P
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):830-3. PubMed ID: 21171270
[TBL] [Abstract][Full Text] [Related]
42. [The mRNA expression of P16(ink4a) and HST2 in benign prostatic hyperplasia tissues: a pilot study].
Xiong Y; Pan TJ; Ye ZQ
Zhonghua Nan Ke Xue; 2008 Mar; 14(3):224-6. PubMed ID: 18488334
[TBL] [Abstract][Full Text] [Related]
43. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
44. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
Floriano-Sánchez E; Cárdenas-Rodríguez N; Castro-Marín M; Alvarez-Grave P; Lara-Padilla E
Clin Invest Med; 2009 Dec; 32(6):E258. PubMed ID: 20003831
[TBL] [Abstract][Full Text] [Related]
45. Can noninvasive evaluation of benign prostatic obstruction be optimized?
Løvvik A; Yaqub S; Oustad H; Sand TE; Nitti VW
Curr Opin Urol; 2012 Jan; 22(1):1-6. PubMed ID: 22080874
[TBL] [Abstract][Full Text] [Related]
46. NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas.
Borchers H; Meyers FJ; Gumerlock PH; Stewart SL; deVere White RW
J Urol; 1996 Jun; 155(6):2080-4. PubMed ID: 8618340
[TBL] [Abstract][Full Text] [Related]
47. [Application of infrared image system in the diagnosis of chronic prostatitis and benign prostatic hyperplasia].
Tian YH; Xiong CL
Zhonghua Nan Ke Xue; 2003 Jun; 9(3):204-6. PubMed ID: 12861837
[TBL] [Abstract][Full Text] [Related]
48. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
49. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
51. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
52. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis.
Vermassen T; Van Praet C; Poelaert F; Lumen N; Decaestecker K; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Biochem Med (Zagreb); 2015; 25(3):439-49. PubMed ID: 26526330
[TBL] [Abstract][Full Text] [Related]
54. Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia.
Özdemir TR; Şimşir A; Onay H; Cüreklibatır İ; Özkınay F; Akın H
Urol Oncol; 2017 Oct; 35(10):607.e15-607.e24. PubMed ID: 28647394
[TBL] [Abstract][Full Text] [Related]
55. The prognostic use of inflammation and tissue necrosis in benign prostatic hyperplasia.
Willder JM; Walker VC; Halbert GL; Dick CP; Orange C; Qayyum T; Horgan PG; Underwood MA; Edwards J
Urol Int; 2013; 91(1):19-25. PubMed ID: 23306308
[TBL] [Abstract][Full Text] [Related]
56. Inflammation and benign prostatic hyperplasia.
Nickel JC
Urol Clin North Am; 2008 Feb; 35(1):109-15; vii. PubMed ID: 18061029
[TBL] [Abstract][Full Text] [Related]
57. Inflammation and benign prostatic hyperplasia: clinical implications.
Chughtai B; Lee R; Te A; Kaplan S
Curr Urol Rep; 2011 Aug; 12(4):274-7. PubMed ID: 21519898
[TBL] [Abstract][Full Text] [Related]
58. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases.
Bardan R; Dumache R; Dema A; Cumpanas A; Bucuras V
Clin Biochem; 2014 Jul; 47(10-11):909-15. PubMed ID: 24560954
[TBL] [Abstract][Full Text] [Related]
59. Re: Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.
Schaeffer EM
J Urol; 2012 Sep; 188(3):834-5. PubMed ID: 22883768
[No Abstract] [Full Text] [Related]
60. Comparison of cytokine levels in prostatic secretion between the IIIa and IIIb subtypes of prostatitis.
Han CL; Deng YX; Hu P; Hu BT; Wang T; Liu JH; Li MC
Asian J Androl; 2023 Aug; 26(1):77-84. PubMed ID: 37695210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
